Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, HV, Amsterdam, The Netherlands.
Cancer Center Amsterdam, Cancer Biology and Immunology, HV, Amsterdam, The Netherlands.
Immunol Rev. 2023 Mar;314(1):280-301. doi: 10.1111/imr.13159. Epub 2022 Nov 4.
Tumor-targeting monoclonal antibodies are available for a number of cancer cell types (over)expressing the corresponding tumor antigens. Such antibodies can limit tumor progression by different mechanisms, including direct growth inhibition and immune-mediated mechanisms, in particular complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and antibody-dependent cellular cytotoxicity (ADCC). ADCC can be mediated by various types of immune cells, including neutrophils, the most abundant leukocyte in circulation. Neutrophils express a number of Fc receptors, including Fcγ- and Fcα-receptors, and can therefore kill tumor cells opsonized with either IgG or IgA antibodies. In recent years, important insights have been obtained with respect to the mechanism(s) by which neutrophils engage and kill antibody-opsonized cancer cells and these findings are reviewed here. In addition, we consider a number of additional ways in which neutrophils may affect cancer progression, in particular by regulating adaptive anti-cancer immunity.
肿瘤靶向单克隆抗体可用于许多表达相应肿瘤抗原的癌细胞类型。这些抗体可以通过不同的机制限制肿瘤的进展，包括直接生长抑制和免疫介导的机制，特别是补体依赖性细胞毒性、抗体依赖性细胞吞噬作用和抗体依赖性细胞细胞毒性（ADCC）。ADCC 可以由各种类型的免疫细胞介导，包括中性粒细胞，这是循环中最丰富的白细胞。中性粒细胞表达多种 Fc 受体，包括 Fcγ-和 Fcα-受体，因此可以杀死与 IgG 或 IgA 抗体结合的肿瘤细胞。近年来，人们对中性粒细胞与抗体包被的癌细胞结合并杀死它们的机制有了重要的了解，本文对此进行了综述。此外，我们还考虑了中性粒细胞可能通过调节适应性抗癌免疫来影响癌症进展的其他一些方式。
